Ted Driscoll’s WSJ interview: 23andMe Flap With FDA Just a Bump in the Road, One Genetics-Testing Investor Says

WallStreetJournalLogo

source: by Timothy Hay

When the Food and Drug Administration told personal-genetics company 23andMe Inc. in November to stop sending consumers detailed information about their DNA, some industry watchers said the move could be a devastating blow to an emerging area of medicine that holds promise for better health outcomes.

But it was more of a flesh wound, said Claremont Creek Ventures Director Ted Driscoll. Though not an investor in 23andMe, he has . . .
→ Read full post: Ted Driscoll’s WSJ interview: 23andMe Flap With FDA Just a Bump in the Road, One Genetics-Testing Investor Says

Entrepreneurs: The End Is Near. Refinance.

John Steuart

September 28, 2011 source: Wall Street Journal

All good things, unfortunately, come to an end. The last year or two have been spectacular for entrepreneurs. Investor enthusiasm has been intense, meaning that start-ups had the upper hand and could get financing at extraordinarily generous terms.

But I’m afraid that the curtain is about to fall. All signs point to the imminent arrival of a radically different funding environment. When? Perhaps as early as . . .
→ Read full post: Entrepreneurs: The End Is Near. Refinance.

Goldhaber claims there’s still plenty of investor enthusiasm for companies that are installing or financing solar projects

September 23, 2011 source: Forbes

What the Solyndra Bankruptcy Means for Cleantech Investors

by Jennifer Kho. Forbes Contributor

As executives of defunct solar-panel manufacturer Solyndra keep mum in Washington, Silicon Valley and Wall Street are discussing what the bankruptcy – and the federal investigation – could mean for investors.

“It has an impact; it’s such a big story,” says Sheeraz Haji, CEO of research firm Cleantech Group.

In what some are calling “the . . .
→ Read full post: Goldhaber claims there’s still plenty of investor enthusiasm for companies that are installing or financing solar projects

IPOs look dicey, but private equity may pick up some of the slack

Randy Hawks

September 15, 2011 source: Xconomy

For a while, I was optimistic that 2011 would be a good year for venture capital-backed IPOs, and it wasn’t just wishful thinking. There were 72 VC-backed IPOs last year—six times as many as in 2009. The year ended with a bang and 2011 got off to a good start. In the first half of 2011, there were 36 IPOs, right on target for at least a replay . . .
→ Read full post: IPOs look dicey, but private equity may pick up some of the slack

Will the Stem Cell Ruling Affect Venture Capital Investing?

September 1, 2010 source: xconomy Brad Webb, Venture Partner at Claremont Creek Ventures, was featured today on the xcononomy website discussing the implications for venture investment of the recent judicial ruling regarding federal funding for stem cell research. Last week’s federal district court ruling ordering an immediate halt in federal funding for stem cell research has thrown academic research circles into a state of confusion. This has caught the attention of the VC community, . . .
→ Read full post: Will the Stem Cell Ruling Affect Venture Capital Investing?